Chinese Academy of Sciences collaborate on antibody drug development
On March 7th, MRC Technology (Medical Research Council Technology transfer charity, UK) and Institut Pasteur of Shanghai, Chinese Academy of Sciences - IPS-CAS signed a collaboration agreement to develop new therapeutic antibodies from research originating in China.
Monoclonal antibody-based drugs have been established as one of the most successful therapeutic strategies for the treatment of infectious diseases, cancers and autoimmune diseases. “The promise of immune check-point antibodies and broadly neutralizing antibodies against pathogens brings a boom in research and research development across the world, which makes this collaboration all the more significant and important”, said Professor Sun Bing, the Director of IPS-MRCT Joint Centre for Therapeutic Antibodies.
Read more on IPS-CAS website: here
![](https://static.wixstatic.com/media/75d19e_d48b62547da4466883b811d0b44a8567~mv2.jpg/v1/fill/w_190,h_32,al_c,q_80,blur_3,enc_auto/75d19e_d48b62547da4466883b811d0b44a8567~mv2.jpg)